Biotech | March 16, 2022
Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
The focus is to build collaborative learning and sharing ecosystem
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Macitentan tablets, 10 mg have an estimated market size of US $ 797 million for twelve months ending Dec 2021 according to IQVIA
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Subscribe To Our Newsletter & Stay Updated
